Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients
Objectives: HBV infection is a global public health problem. Tenofovir disoproxil fumarate and tenofovir alafenamide are nucleotide reverse transcriptase inhibitors and used for the treatment of chronic Hepatitis B infection. The aim of this study was to evaluate treatment response and efficacy of Tenofovir disoproxil fumarate. Materials and Methods: The study included hepatitis B positive patients who started to use Tenofovir disoproxil fumarate. We retrospectively reviewed electronic medical files of Hepatitis B patients. Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B e antigens, Hepatitis B e antibody, Hepatitis B viral DNA, aspartate aminotransferase, alanine aminotransferase values were evaluated in the 1st, 3rd, 6th, 9th, and 12th months. Result: None of the patients under Tenofovir disoproxil fumarate treatment was “primary resistant”. Alanine aminotransferase normalization at 12th month was seen in 80.4% of study population. Hepatitis B surface antigen seroconversion was detected only in one patient (0.85%) at 9th months and Hepatitis B e antigen seroconversion was observed in 9 patients (8.3%) under Tenofovir disoproxil fumarate treatment. At the sixth month of Tenofovir disoproxil fumarate treatment, complete response was found in 77 (65.8%), partial response in 21 (18%) and inadequate response were in 19 (16.2%). Among Hepatitis B e antigen positive patients, 44 (80 %) patients had undetectable Hepatitis B virus DNA levels at the end of 12th month and among Hepatitis B e antigens negative patients, 52 (91.2%) patients had undetectable Hepatitis B DNA levels at the end of 12th month (p
___
[1] Sarin S, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology international 2016; 10(1): 1-98.[2] Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43: S173-S81.
[3] McMahon BJ. Epidemiology and natural history of hepatitis B. Seminars in liver disease 2005;25(1):3-8.
[4] Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007;45(1):97-01.
[5] Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560-99.
[6] Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295(1):65-73. [7] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507-39.
[8] Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology & Hepatology 2016;1(3):185-95.
[9] Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clinical Gastroenterology and Hepatology 2007;5(8):890-7.
[10] ABIM laboratory test reference ranges. https://www.abim. org/~/media/ABIM%20Public/Files/pdf/exam/laboratory-reference-ranges.pdf (Accessed January 2020) [11] Tang LS, Covert E, Wilson E, et al. Chronic Hepatitis B Infection: A Review. Jama 2018;319(17):1802-13.
[12] Güzelbulut F, Ovünç A, Oetinkaya Z, et al. Comparison of the efficacy of entecavir and tenofoviin chronic hepatitis B. Hepato-gastroenterology 2012;59(114):477-80.
[13] Başarir İ, İlikhan S, Soyaltin UE. Kronik aktif hepatit B tanılı hastalarımızın tedavi yanıtlarının değerlendirilmesi. Akademik Gastroenteroloji Dergisi 2013; 12(2):58-65.
[14] Demir NA, Kölgelier S, Demir LS. Naif Kronik Hepatit Bhastalarinin Bir Yillik 245 Mg/Gün Tenofovir Disoproksil Fumarate Tedavi Sonuçlarinin Değerlendirilmesi. Evaluation 2013; 21:25.
[15] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. The New England journal of medicine 2008;359(23):2442-55.
[16] Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139(4):1218-1229.
[17] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560
[18] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: arandomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:196.
[19] İnkaya A, Türk Arıbaş e, Kandemir B, et al. Role of Tumor Necrosis Factor alpha promoter polymorphisms in interferon related side effects in chronic hepatitis B patients under interferon alpha 2b treatment. Acta Medica 2019; 50(2): 32 - 38.
[20] Keskin O, Ormeci AC, Baran B, et al. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. Antivir Ther. 2014;19(6):543-50.
- ISSN: 2147-9488
- Yayın Aralığı: Yılda 4 Sayı
- Başlangıç: 2012
- Yayıncı: HACETTEPE ÜNİVERSİTESİ
Sayıdaki Diğer Makaleler
Süreyya TALAY, Nahide BELGİT TALAY
Özlem DİKMETAŞ, Bogomil VOYKOV
The Impact of Noise on Hearing in Intensive Care Unit Nurses
Süheyla ABİTAĞAOĞLU, Alev ÖZTAŞ, Fatma ŞİMŞEK CEVİZ, Ceren KÖKSAL, Tuğba ASLAN DÜNDAR, Güldem TURAN, Dilek ERDOĞAN ARI
Gamze DURHAN, Ömer ÖNDER, Aynur AZİZOVA, Jale KARAKAYA, Kemal KÖSEMEHMETOĞLU, Meltem Gülsüm AKPINAR, Figen DEMİRKAZIK
Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients
Seval Müzeyyen ERCİN, Nursel ÇALIK BAŞARAN, Murat ALADAĞ
Our Experience in Hepatoblastoma Surgery
Önder ÖZDEN, Şeref Selçuk KILIÇ, Abdullah ÜLKÜ, Gülay SEZGİN, Recep TUNCER